Aservo EquiHaler wins Red Dot 2020 for design quality Aservo EquiHaler wins Red Dot 2020 for design quality Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality
Collaboration-with-OxfordBioTherapeutics Collaboration-with-OxfordBioTherapeutics Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
expanded-collaboration-MD-Anderson expanded-collaboration-MD-Anderson The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Animal Health partnering interests Animal Health partnering interests Animal Health partnering interests
ArisGlobal acquires Boehringer Ingelheim technology ArisGlobal acquires Boehringer Ingelheim technology Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
FDA Grants Breakthrough Status to Schizophrenia Treatment FDA Grants Breakthrough Status to Schizophrenia Treatment Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products
GastroGard the first imported equine drug in China GastroGard the first imported equine drug in China GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Winners of 2020 BVDzero Case Awards Winners of 2020 BVDzero Case Awards Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.
Partnership to Develop Urea Cycle Disorders Therapy Partnership to Develop Urea Cycle Disorders Therapy Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
LastMile increases access to veterinary care in Africa LastMile increases access to veterinary care in Africa Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
Boehringer Ingelheim half-year results 2023 Boehringer Ingelheim half-year results 2023 First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Option to Acquire Trutino Biosciences Option to Acquire Trutino Biosciences Option to Acquire Trutino Biosciences
Strategic-collaboration-with-EnaraBio Strategic-collaboration-with-EnaraBio Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Koropi Koropi For more than 45 years, the company has been producing pharmaceuticals in its production facility in Koropi, Greece.
Nerandomilast (BI 1015550): PDE4B inhibitor Nerandomilast (BI 1015550): PDE4B inhibitor Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor Nerandomilast (BI 1015550): PDE4B inhibitor Nerandomilast (BI 1015550): PDE4B inhibitor
inauguration_biopharmaceutical_production_facility_vienna inauguration_biopharmaceutical_production_facility_vienna The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
Phase 1 start of treatment for Geographic Atrophy patients Phase 1 start of treatment for Geographic Atrophy patients Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)
PRRS Research Award 2022 PRRS Research Award 2022 Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
It is about saving lives Alexis Jaliquias feline blood bank It is about saving lives Alexis Jaliquias feline blood bank Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America
Partnership to further develop pet market in China Partnership to further develop pet market in China Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies